TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report issued on Sunday. The brokerage issued a hold rating on the stock.

TherapeuticsMD Stock Performance

TXMD opened at $1.14 on Friday. TherapeuticsMD has a 1-year low of $1.10 and a 1-year high of $2.75. The company’s fifty day moving average price is $1.44 and its two-hundred day moving average price is $1.66.

Hedge Funds Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP raised its stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the quarter. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.